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Editorial on the Research Topic
Sudden Cardiac Death and Channelopathies
Sudden cardiac death has serious consequences for the patient’s relatives and for society. Each year
in Europe and the USA, around 350,000 people, or around 0.1% of the general population, have an
out-of-hospital cardiac arrest, of which only a small percentage survive with no sequelae.
The etiology of sudden death has been extensively studied at a population level. Ischemic heart
disease occupies a prominent position and is responsible for up to 70% of these deaths; other
structural heart diseases make up 10%, and primary arrhythmias cause a further 10%.
In young patients (less than 35 years of age), in whom the incidence of sudden death is 100
times lower than in the general population, arrhythmic etiology, mainly from channelopathies, in
the absence of structural heart disease is much more common and is the predominant cause of
sudden death in patients aged between 14 and 25 years. In older patients channelopathies such as
Brugada syndrome are more likely to occur in the fourth decade of life.
The channelopathies responsible for sudden cardiac death are: Long QT syndrome, Short
QT syndrome, Brugada syndrome, Catecholaminergic Polymorphic Ventricular Tachycardia
syndrome, and Early repolarization Syndrome.
Early identification and risk stratification is of major importance in patients with a
channelopathy who remain asymptomatic, for several reasons. First, sudden death may be the
first manifestation of the disease, with no previous warning symptoms. In addition, it should be
considered that when we diagnose a patient with a hereditary disease, we also diagnose their family.
Identification of an individual with this condition must be accompanied by meticulous familial
screening. It is true that in these diseases the risk of sudden death decreases with age, but even a
diagnosis in an elderly patient is relevant, as it allows identification of the disease in relatives and
their appropriate work-up.
The scope of the Research Topic is to collect state-of-the art papers on what we know so
far for all types of Long QT syndromes, Brugada Syndrome, Early repolarization Syndrome,
Catecholaminergic Polymorphic Ventricular Tachycardia, and Short QT syndrome. Furthermore,
our aim is to provide further insight on the current research areas, and which should be the area’s
future perspectives.
Ezeani explored one of the numerous mechanisms with which the arrhythmias present.
Identifying the sources that control Ca2+ is novel in understanding arrhythmogenesis. The TRP
channels mediate Ca2+ flux and voltage changes across membranes. Regulation of Ca2+-handling
by the TRP channels indicate that they can potentially boost Ca2+ cycling disorders. The plasma
membrane sensory and metabotropic TRPM4 subgroup is a drug candidate for Brugada syndrome
and familial heart blockers.
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Novelli et al. dealt with Pleiotropic Phenotypes Associated with
PKP2 Variants. Their review on plakophilin-2 (PKP2) coded
by the gene Pkp2, whose pathogenic role has recently been
recognized in different inherited cardiac arrhythmias syndromes,
ranging from Arrhythmogenic Cardiomyopathy (ACM or
ARVC), Brugada Syndrome (BrS), idiopathic ventricular
fibrillation, hypertrophic cardiomyopathy (HCM), and dilated
cardiomyopathy (DCM). The expansion and increased
availability of genetic testing has challenged the concept of
“one gene-one disease” and has shown that different phenotypes
can be caused by variants on one same gene. The interpretation
of these findings in light of human variation data is complex
and casts some warning on the clinical application of this
information. The evidence of the pleiotropy of a gene suggested
by genetic variants and their functional effect in vitro has the
important value of discovering different protein functions and
suggest arrhythmia mechanisms.
Badone et al. contributed to the field by reviewing the
Functional Effects of Calmoduline Mutations and Their
Relationship with Clinical Phenotypes. Based on the information
reviewed above, mechanism-guided therapeutic approaches
to calmodulinopathies should ideally address the interaction
of mutant CaM with its targets. Particularly in the case
of LQTS-type mutations, this approach is justified by
the role of the high target affinity of mutant CaMs in
causing negative dominance of the mutation. Tools for this
purpose are not available yet, but possibilities exist and are
currently explored.
Kotta et al. present in a detailed CaM’s sequence, structure
and function, the genetic spectrum of CaM mutations and
the associated phenotypes, as well as available therapies. They
also provide an overview of the underlying disease mechanisms
of calmodulinopathy (reviewed in detail in the accompanying
article by Badone et al.) and present the thus far used in vitro
methods for deciphering these disease mechanisms.
Casado Arroyo et al. provided an overview for the
current evidence supporting different theories explaining Early
Repolarization Syndrome. Along with future developments in
the field directed toward individualized treatment, strategies
are also examined. Bourier et al. add significantly to the field
of ER syndrome, suggesting a risk stratification approach and
therapeutic management.
Baltogiannis et al. presented Catecholaminergic Polymorphic
Ventricular Tachycardia (CPVT) in this collection, as
arrhythmogenesis, therapeutic Management, and Future
Perspectives are still challenging. Dutsi et al. provided,
in detail, the therapeutic impact of Cardiac Sympathetic
Denervation in Cardiac Channelopathies. clinical data from
well-conducted multicenter registries largely confirmed the
preclinical findings, showing that LCSD is an effective treatment
for drug-refractory ventricular arrhythmias in both LQTS and
CPVT, and that LCSD is now recommended in recent guidelines.
Not surprisingly, considering the mechanism of action, the
efficacy and potential indication of LCSD in channelopathies
goes far beyond secondary prevention, potentially including
many still asymptomatic patients with high-risk features for
SCD, despite optimized medical therapy.
Campuzano et al. offered a mini review in Recent Advances
in Short QT Syndrome. Nearly 20 years ago, SQTS was reported
as a familial arrhythmogenic entity. Nowadays, a low number of
families have been reported but with a high lethality. This lack
reported families, impedes the establishment of a conclusive risk
stratification scale, particularly in asymptomatic cases carrying
a genetic alteration. New development of hiPSC-CMs from
patients may allow unraveling pathophysiological mechanism,
helping to understand or treat the disease. Patients suffering
of SQTS are at high risk of syncope and SCD. Implantation
of an ICD remains the most effective preventive measure after
aborted SCD and malignant ventricular arrhythmia, although
pharmacological therapiesmay be used in certain cases, especially
in children. Currently, regardless of advances being made in
genetics, almost 70–80% of families remain without a genetic
cause identified after a comprehensive analysis. Genotype-
phenotype analysis are necessary to improve current guidelines
in early identification as well as prevention in families suffering
from SQTS. On the other hand, Wilders and Verkerk dealt with
Long QT Syndrome and Sinus Bradycardia. Sinus bradycardia
has been reported in relation to a large number of LQTS
mutations. The occurrence of both QT prolongation and sinus
bradycardia on a family basis is almost completely limited
to LQT3 and Ankyrin-B syndrome (“LQT4”). However, the
mechanisms of the associated ventricular arrhythmias and
sudden death are largely different. Cardiac events, including
nocturnal sudden death, are provoked by the bradycardia and
associated excessive QT prolongation in case of LQT3, whereas
disturbed calcium homeostasis leads to dysfunction of the SAN
cells in case of the Ankyrin-B syndrome, with sudden death
occurring after physical exertion and emotional stress.
Moreau and Chahine have added significant value on the
topic by introducing a New Cardiac Channelopathy Associated
with Nav1.5 Gating Pores. The potential cardiac cellular effects
of gating pores and their blockers are also presented here. The
increasing knowledge regarding gating pores and their pathologic
implication, potentially highlights novel biophysical defects and
consequently novel channelopathies. In the current dynamic
toward more precise and personalized medicine, this growing
knowledge could in the future orientate clinicians in their day
to day practice in the management of cardiac channelopathies.
This could also help to develop specifically targeted novel
medication to accurately and precisely block gating pores, finally
benefitting patients.
Verkerk et al. analyzed all possible disease modifiers of
Inherited SCN5A Channelopathy. Genetic modifiers, (common)
co-morbidities, environmental influences, and life style factors
including diet and exercise may modify disease expressivity
and severity, and as such significantly modulate the risk for
arrhythmia occurrence and survival in SCN5A channelopathy.
Importantly, the impact of modulatory factors may differ
between distinct mutations but may also vary with age and
gender. Hence, the clinical management of patients with SCN5A
mutations should include careful and continuous assessment of
co-existing diseases and other modulatory factors, in addition
to rigorous treatment of relevant co-morbidities. Identification
of disease modifiers will be an essential step in further research
Frontiers in Cardiovascular Medicine | www.frontiersin.org 2 November 2020 | Volume 7 | Article 605834
Baltogiannis et al. Editorial: Sudden Cardiac Death and Channelopathies
related to SCN5A channelopathies and may help to design better
risk stratification algorithms and to improve development of
novel diagnostic and therapeutic strategies. Tse et al. provided
electrocardiographic evidence that higher levels of dispersion in
conduction and repolarization are found in type 1 than non-type
1 BrS patients. This may potentially explain the higher incidence
of ventricular arrhythmias in the former group. Indices reflecting
cumulative conduction and repolarization abnormalities may
provide additional value for risk stratification.
Finally, Cheniti et al. dealt with Mapping and Ablation of
Idiopathic Ventricular Fibrillation. Insights in pathophysiology
of idiopathic VF are presented. Idiopathic VF is diagnosed in
around one third of survivors of unexplained SCD aged under
35 years. Genetic testing allows identification of a likely causative
mutation in around one quarter of unexplained sudden deaths in
children and young adults. Ablation of the PVCs that trigger VF
in this setting is associated with high rates of acute success and
long-term freedom from VF recurrence. Importantly, almost two
thirds of patients have subtle structural abnormalities identified
by high density electrogram mapping which are missed by
current imaging tools. This localized substrate, which co-locates
with regions of VF drivers, provides an explanation for so
called unexplained SCD and represents a novel potential target
for ablation.
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